Uncategorized
Potential FDA pick favors approving drugs before efficacy demonstrated
President Donald J. Trump is said to be considering picking former HHS official Jim O’Neill to lead the FDA, a move that would signal the administration is serious about loosening regulations on the drug approval process.Trump has yet to name a replacement for Robert M. Califf, MD, who stepped down as FDA commissioner when the new president was inaugurated, according to tradition. He would likely find an ally in O’Neill, who appears to favor the approval of drugs before their efficacy has been established.